MedinCell Investor Relations Material
Latest events
H2 24/25
MedinCell
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from MedinCell S.A.
Access all reports
MedinCell S.A. is a pharmaceutical company specializing in the development of long-acting injectable therapies using its proprietary BEPO technology. This technology allows for the sustained release of active pharmaceutical ingredients over several days, weeks, or months from a single, bioresorbable injection. The company's portfolio includes products targeting various therapeutic areas, with a focus on treating conditions such as schizophrenia and post-surgical pain. MedinCell collaborates with global pharmaceutical companies and organizations to advance its product pipeline. The company is headquartered in Jacou, France, and its shares are listed on the Euronext Paris.
Key slides for MedinCell S.A.
H2 24/25
MedinCell S.A.
H1 24/25
MedinCell S.A.
Latest articles
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
Ticker symbol
MEDCL
Country
🇫🇷 France